Business
Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer - WALTHAM, Mass., March 30, 2023 /PRNewswire/
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer -\nWALTHAM, Mass., March 30, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Neil Gallagher, M.D., Ph.D., to the role of President, Head of Research and Development (R&D), effective April 10, 2023. Dr. Gallagher brings to Syndax over 20 years of industry experience, most recently serving as Chief Medical Officer, Vice President, Head of Development at AbbVie, where he led multiple development programs through approval globally and oversaw asset strategy and portfolio management across several therapeutic areas, including oncology.\n\"Neil is a preeminent, global oncology drug developer with deep expertise and a strong track record of successful drug approvals, notably in hematologic malignancies with Venclexta®, an important new agent for patients with acute leukemia,\" said Michael A. Metzger, Chief Executive Officer. \"Neil's passion for bringing innovative drugs to patients and his experience across all stages of drug development will be instrumental as we advance revumenib and axatilimab through anticipated pivotal data readouts and two planned regulatory filings expected in 2023. I look forward to Neil's many contributions as we work to bring novel products to patients and pursue opportunities to expand our pipeline of best-in-class medicines.\"\nPrior to assuming his role as Chief Medical Officer, Vice President, Head of Development at AbbVie, Dr. Gallagher served as the company's Head of Global Oncology Development, a role in which he expanded the hematology and solid tumor portfolio while strengthening precision medicine and companion diagnostic capabilities. Prior to joining AbbVie, he served as Head of Development for Oncology and Inflammation at Amgen. Dr. Gallagher previously spent a decade at Novartis, where he led several development and clinical programs across the portfolio. While at Novartis, he also led cross-functional global program teams responsible for chronic myeloid leukemia and gastrointestinal stromal tumor development as well as other hematology oncology indications. Earlier in his career, he was a Senior Medical Director at AstraZeneca and lat...